Trends in Epilepsy Research
FAST launches a new biotech to find cures for Angelman syndrome
03/20/2018
The Foundation for Angelamn Syndrome Therapeutics (FAST) launches a new biotech, GeneTx Biotherapeutics LLC (GeneTx), a subsidiary of FAST, for the development and commercialization of an investigational antisense drug, GTX-101, for the treatment of Angelman syndrome (AS), a rare genetic disorder characterized by epilepsy, impaired motor function and speech delays. Read More
Epidiolex shows promise in some Dravet syndrome patients
03/20/2018
A recent study published in the New England Journal of Medicine (NEJM) shows a purified cannabidiol (CBD) medication called Epidiolex may help to curb seizures in children and young adults with Dravet syndrome. Read More
Former British Prime Minister shares the lessons he learnt from his son's rare epileptic syndrome
03/02/2018
David Cameron’s son Ivan was born with a neurological disorder that baffled doctors. He was later diagnosed with a rare epileptic syndrome, Ohtahara syndrome. Now, he writes, genomic testing can end the anguish of uncertainty.